USRM
$USRM From .0045 Onwards She is Ready for the 4th Leg UpBy far one of my top 3 favorite stocks so far this year, our Bio baby has proven her stamina. She has hit the .08 support at triple bottom and is ready for a 4th massive move upwards. With Institutional investors now throwing upwards of $5 million in financing at her for a stake in what is to be a potential FDA approval after a more than likely RMAT approval, its no wonder she is up almost 20,000% as of today from where we first found her. This is a perfect time to get back in if you already sold and are looking for another entry point for the next leg up.
$OWCP Why I'm Extremely Long on This $5.00 by EOMI was in on the initial run .0030 - .10 bought and sold from .10 - $3.00 bought and sold (both times sold too early) and now .50 - $5.00 Here's why:
PROVISIONAL PATENTS TAKE ABOUT 8-12 MONTHS TO GET TURNED INTO APPROVED PATENTS.
Here's the list of $OWCP Patents:
1) patentscope.wipo.int
2) patentscope.wipo.int
3) patentscope.wipo.int
4) patentscope.wipo.int
5) patentscope.wipo.int
6) patentscope.wipo.int
7) patentscope.wipo.int
Also the Patent Document: www.docdroid.net
FROM THE 8K ON APRIL 4TH: OWC Pharmaceutical Research Corp. ("OWC") is reporting the issuance on April 5, 2017 of the attached press release, announcing that as a result of the promising conclusions reported in its Form 8-K filed on March 20, 2017, the Company has received expressions of scientific and medical interest, world-wide, for its cannabinoid-based topical cream for treating psoriasis. OWCP has expanded the size and scope of its clinical studies and, as previously announced, anticipates that subject to pending regulatory approvals from applicable jurisdictions, the topical cream should be available for use by those who suffer from psoriasis in the near term.
ALSO LETS NOT FORGET 4/20
In addition we have many news outlets covering MJ which is bringing it back into the light.
CANADA LEGALIZING IT NATIONWIDE.
Too many catalysts to cover.
Once we break key resistance tomorrow we could see $2.00 by EOD
$USRM Alerted from .012 Currently on 3rd Major Breakout Setup$USRM is currently awaiting RMAT designation which approved (And there is a 90% or higher chance it will) gives it similar qualities as Breakthrough Therapy, Accelerated Approval, and Priority Review. Basically, they can provisionally approve the drug or device for marketing and then provided the drug or device proves safe and reasonably effective, they will gain full approval - generally within 6 months.
Other DD:
1. Institutional Loading
2. Multiple Patents
3. Nice ER that showed substantial profits
4. PreClinical Study Results Anyday
5. Form 4s filed by insiders
6. Uplistment